Scott Sproul

598 total citations
17 papers, 461 citations indexed

About

Scott Sproul is a scholar working on Molecular Biology, Physiology and Genetics. According to data from OpenAlex, Scott Sproul has authored 17 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Physiology and 7 papers in Genetics. Recurrent topics in Scott Sproul's work include CRISPR and Genetic Engineering (10 papers), Lysosomal Storage Disorders Research (8 papers) and Virus-based gene therapy research (7 papers). Scott Sproul is often cited by papers focused on CRISPR and Genetic Engineering (10 papers), Lysosomal Storage Disorders Research (8 papers) and Virus-based gene therapy research (7 papers). Scott Sproul collaborates with scholars based in United States. Scott Sproul's co-authors include Michael C. Holmes, Thomas Wechsler, Russell C. DeKelver, Shangzhen Zhou, Katherine A. High, David E. Paschon, Jeffrey C. Miller, Robert J. Davidson, Rajiv P. Sharma and Julianne Rieders and has published in prestigious journals such as Blood, Cancer Research and Molecular Therapy.

In The Last Decade

Scott Sproul

17 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Sproul United States 5 344 227 149 71 68 17 461
Kanut Laoharawee United States 8 235 0.7× 141 0.6× 111 0.7× 85 1.2× 53 0.8× 25 357
Aaron S. Meadows United States 11 189 0.5× 178 0.8× 176 1.2× 40 0.6× 86 1.3× 13 383
Carl A. Mitchell United States 8 282 0.8× 61 0.3× 50 0.3× 32 0.5× 26 0.4× 9 521
Chester Li United States 7 149 0.4× 140 0.6× 161 1.1× 31 0.4× 103 1.5× 8 320
Ayn Schneider United States 6 187 0.5× 250 1.1× 262 1.8× 32 0.5× 107 1.6× 7 459
Federico Mingozzi France 6 232 0.7× 198 0.9× 59 0.4× 79 1.1× 53 0.8× 6 352
Mintie Pu United States 7 659 1.9× 129 0.6× 51 0.3× 31 0.4× 54 0.8× 10 750
Elena Barbon France 10 292 0.8× 171 0.8× 19 0.1× 54 0.8× 33 0.5× 17 386
Kai‐Hsin Chang United States 13 262 0.8× 64 0.3× 109 0.7× 43 0.6× 12 0.2× 15 540
Emily M. King United States 4 304 0.9× 191 0.8× 24 0.2× 28 0.4× 18 0.3× 6 363

Countries citing papers authored by Scott Sproul

Since Specialization
Citations

This map shows the geographic impact of Scott Sproul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Sproul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Sproul more than expected).

Fields of papers citing papers by Scott Sproul

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Sproul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Sproul. The network helps show where Scott Sproul may publish in the future.

Co-authorship network of co-authors of Scott Sproul

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Sproul. A scholar is included among the top collaborators of Scott Sproul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Sproul. Scott Sproul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Pagant, Silvère, Luciana Moreira, Lin Gan, et al.. (2021). ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice. Molecular Therapy. 29(11). 3230–3242. 13 indexed citations
2.
Yasuda, Makiko, Silvère Pagant, Lin Gan, et al.. (2020). AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Molecular Therapy — Methods & Clinical Development. 18. 607–619. 41 indexed citations
3.
Ou, Li, Russell C. DeKelver, Michelle Rohde, et al.. (2018). ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome. Molecular Therapy. 27(1). 178–187. 64 indexed citations
4.
Laoharawee, Kanut, Russell C. DeKelver, Kelly M. Podetz-Pedersen, et al.. (2018). Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing. Molecular Therapy. 26(4). 1127–1136. 91 indexed citations
5.
Pagant, Silvère, Makiko Yasuda, Susan S. Martin, et al.. (2018). ZFN-mediated in vivo genome editing results in therapeutic levels of α-galactosidase A and effective substrate reduction in Fabry knockout mice. Molecular Genetics and Metabolism. 123(2). S113–S113. 1 indexed citations
6.
Wechsler, Thomas, Russell C. DeKelver, Kanut Laoharawee, et al.. (2018). ZFN-mediated in vivo genome editing of hepatocytes results in phenotypic correction in murine MPS I and MPS II models. Molecular Genetics and Metabolism. 123(2). S146–S147. 1 indexed citations
7.
Yasuda, Makiko, Silvère Pagant, Susan S. Martin, et al.. (2018). Liver-based expression of the human alpha-galactosidase A gene in a murine Fabry model results in continuous therapeutic levels of enzyme activity and effective substrate reduction. Molecular Genetics and Metabolism. 123(2). S68–S68. 1 indexed citations
8.
DeKelver, Russell C., Li Ou, Kanut Laoharawee, et al.. (2017). ZFN-mediated in vivo genome editing results in phenotypic correction in murine MPS I and MPS II models. Molecular Genetics and Metabolism. 120(1-2). S41–S41. 1 indexed citations
9.
Yasuda, Makiko, Silvère Pagant, Susan S. Martin, et al.. (2017). Liver-based expression of the human alpha-galactosidase A gene (GLA) in a murine Fabry model results in continuous supra-physiological enzyme activity and effective substrate reduction. Molecular Genetics and Metabolism. 120(1-2). S69–S69. 1 indexed citations
10.
Ou, Li, Russell C. DeKelver, Susan Tom, et al.. (2016). ZFN-mediated correction of murine MPS I model by expression of the human IDUA cDNA from the albumin “safe harbor” locus. Molecular Genetics and Metabolism. 117(2). S89–S89. 1 indexed citations
11.
Ou, Li, Russell C. DeKelver, Susan Tom, et al.. (2016). 485. ZFN-Mediated Liver-Targeting Gene Therapy Corrects Systemic and Neurological Disease of Mucopolysaccharidosis Type I. Molecular Therapy. 24. S192–S193. 1 indexed citations
12.
Laoharawee, Kanut, Russell C. DeKelver, Susan Tom, et al.. (2016). 484. In Vivo Zinc-Finger Nuclease Mediated Iduronate-2-Sulfatase (IDS) Target Gene Insertion and Correction of Metabolic Disease in a Mouse Model of Mucopolysaccharidosis Type II (MPS II). Molecular Therapy. 24. S192–S192. 1 indexed citations
13.
Wechsler, Thomas, Kathleen Meyer, S. Kaye Spratt, et al.. (2015). ZFN-Mediated Gene Targeting at the Albumin Locus in Liver Results in Therapeutic Levels of Human FIX in Mice and Non-Human Primates. Blood. 126(23). 200–200. 3 indexed citations
14.
DeKelver, Russell C., Michelle Rohde, Susan Tom, et al.. (2015). ZFN-mediated genome editing of albumin “safe harbor” in vivo results in supraphysiological levels of human IDS, IDUA and GBA in mice. Molecular Genetics and Metabolism. 114(2). S36–S36. 3 indexed citations
15.
Wechsler, Thomas, Michelle Rohde, Susan Tom, et al.. (2015). 479. ZFN-Mediated In Vivo Genome Editing Results in Supraphysiological Levels of Lysosomal Enzymes Deficient in Hunter and Hurler Syndrome and Gaucher Disease. Molecular Therapy. 23. S190–S190. 2 indexed citations
16.
Sharma, Rajiv P., Xavier M. Anguela, Yannick Doyon, et al.. (2015). In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood. 126(15). 1777–1784. 235 indexed citations
17.
Bao, Yun, David Merrill, Delphine Le Corre, et al.. (2011). Abstract 3071: Accurate and sensitive detection of KRAS mutations in heterogeneous cancer specimens. Cancer Research. 71(8_Supplement). 3071–3071. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kanut Laoharawee Breakdown of academic impact, for papers by Aaron S. Meadows Breakdown of academic impact, for papers by Carl A. Mitchell Breakdown of academic impact, for papers by Chester Li Breakdown of academic impact, for papers by Ayn Schneider Breakdown of academic impact, for papers by Federico Mingozzi Breakdown of academic impact, for papers by Mintie Pu Breakdown of academic impact, for papers by Elena Barbon Breakdown of academic impact, for papers by Kai‐Hsin Chang Breakdown of academic impact, for papers by Emily M. King
Rankless by CCL
2026